

EXPLORING THE SPECTRUM OF IMMUNOMODULATORY THERAPY IN HEMATOLOGIC MALIGNANCIES

FRIDAY, OCTOBER 17, 2008 | NEW YORK, NEW YORK
11:15 am – 1:00 pm | Waldorf=Astoria | The Starlight Roof - 18th Floor

CORPORATE SUPPORT

This meeting is
made possible by an
educational grant from



SYMPOSIUM ORGANIZER



4325 Alexander Drive
Alpharetta, Georgia
30022-3740, USA
T: +1 770.751.7332
F: +1 770.751.7334
E: meetings@imedex.com
W: www.imedex.com

**Registration is
complimentary**

to attendees of

**Lymphoma & Myeloma
2008: An International
Congress on Hematologic
Malignancies**

EXPLORING THE SPECTRUM OF IMMUNOMODULATORY THERAPY IN HEMATOLOGIC MALIGNANCIES

FRIDAY, OCTOBER 17, 2008
NEW YORK, NEW YORK

11:15 am – 1:00 pm
Waldorf=Astoria
The Starlight Roof, 18th Floor

Moderator:

Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York



FACULTY

Asher A. Chanan-Khan, MD
Department of Medicine,
School of Medicine &
Biomedical Science
Roswell Park Cancer Institute
Buffalo, New York

Morton Coleman, MD
Center for Lymphoma
and Myeloma
Weill Cornell Medical College
New York Presbyterian
Hospital
New York, New York

Paul A. Hamlin, MD
Memorial Sloan-Kettering
Cancer Center
New York, New York

Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan

ACCREDITATION



Imedex®, LLC
is accredited
by the

Accreditation Council
for Continuing Medical
Education to provide
continuing medical
education for physicians.

Imedex designates this
educational activity for a
maximum 1.25 of AMA PRA
Category 1 Credits™.
Physicians should only claim
credit commensurate with
the extent of their
participation in the activity.

WHO SHOULD ATTEND

This educational activity is
specifically designed for
hematologists, oncologists,
internists and other
physicians, physicians-in-
training, and other healthcare
professionals involved and/
or interested in lymphoma,
myeloma and related plasma
cell disorders and their
management.

EDUCATIONAL OBJECTIVES

After successful completion
of this educational activity,
attendees should be able to:

- Discuss emerging therapies in the pipeline for the treatment of lymphoproliferative disorders
- Assess the emerging role of immunomodulatory agents in the treatment of multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma
- Interpret recent results with the use of immunomodulatory agents for the treatment of hematologic malignancies
- Identify future directions with the use of immunomodulatory agents in hematologic malignancies

CONTINUING MEDICAL EDUCATION

11:15 am	Assembly and Lunch
11:35 am	Introductions & opening remarks Morton Coleman, MD
11:40 am	Exploring the mechanisms of activity of IMiD® compounds Asher A. Chanan-Khan, MD
11:55 am	Q&A
12:00 am	Evolution in the therapeutic landscape for multiple myeloma Jeffrey A. Zonder, MD
12:15 pm	Q&A
12:20 pm	Emerging novel therapies for aggressive non-Hodgkin's lymphomas Paul A. Hamlin, MD
12:35 pm	Q&A
12:40 pm	Expanding the therapeutic options in CLL Asher A. Chanan-Khan, MD
12:55 pm	Q&A
1:00 pm	Adjourn